Bone Biologics Q3 EPS Forecast Lowered by Zacks Research

Bone Biologics Corp. (NASDAQ:BBLG) – Zacks Research decreased their Q3 2026 earnings estimates for shares of Bone Biologics in a research note issued to investors on Monday, August 17th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of ($0.19) per share for the quarter, down from their prior forecast of ($0.18). The consensus estimate for Bone Biologics’ current full-year earnings is ($1.17) per share. Zacks Research also issued estimates for Bone Biologics’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($1.23) EPS and FY2027 earnings at ($0.67) EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Bone Biologics Price Performance

Shares of NASDAQ BBLG opened at $0.64 on Thursday. Bone Biologics has a 1-year low of $0.60 and a 1-year high of $4.13. The business’s 50 day moving average is $1.14 and its two-hundred day moving average is $1.22. The stock has a market capitalization of $1.16 million, a P/E ratio of -0.47 and a beta of 0.92.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04).

Institutional Trading of Bone Biologics

An institutional investor recently raised its stake in Bone Biologics stock. DRW Securities LLC grew its holdings in shares of Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent reporting period. Institutional investors own 34.30% of the company’s stock.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.